Literature DB >> 3396477

Antibiotic prophylaxis in aortic and peripheral arterial surgery in the presence of infected extremity lesions. Results of a prospective evaluation.

J V Robbs1, E Reddy, R Ray.   

Abstract

Over a 6-month period 124 patients submitted to aortic or infra-inguinal arterial reconstruction were alternately allocated to receive cloxacillin plus gentamicin (CX/GM) for 48 hours or cefotaxime (CTX) for 24 hours perioperatively. Evaluations during during the first month were performed by a blinded independent observer and patients were followed for between 6 and 20 months. 63 patients received CX/GM and 61 CTX; the groups were matched for sepsis risk factors. Sepsis rates were: groin and abdominal wounds, CX/GM 5.4% (7 of 129), CTX 6.2% (8 of 127); graft, CX/GM 1.5% (1 of 63), CTX 3.3% (2 of 61). The differences were not statistically significant (p greater than 0.05). Virtually all wound infections were superficial (class I) and no late infections have emerged. 56 patients had infected extremity lesions and 68 had no lesion. There was no significant difference in wound or graft sepsis rates between the 2 groups. Positive cultures of groin lymph nodes and/or aortic clot or atheroma did not predispose patients to postoperative sepsis. The organisms cultured from the extremity lesions were not found in infected wounds of abdominal surgery patients. However, species type and antibiotic susceptibility patterns suggest that the same pathogens were present in wound infections as were isolated from the extremity lesions of patients who underwent infra-inguinal surgery. Thus direct, rather than lymphatic, contamination may be the major aetiological factor. Most infecting organisms were susceptible to the antibiotic used.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396477     DOI: 10.2165/00003495-198800352-00030

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  The prophylaxis of surgical wound sepis with cephaloridine-experiences in 2491 general surgical operations and reporting a controlled clinical trial against framycetin.

Authors:  A V Pollock; M Evans
Journal:  J Antimicrob Chemother       Date:  1975       Impact factor: 5.790

2.  The epidemiology of 2056 remote site infections and 1966 surgical wound infections occurring in 1865 patients: a four year study of 40,923 operations at Rush-Presbyterian-St. Luke's Hospital, Chicago.

Authors:  L D Edwards
Journal:  Ann Surg       Date:  1976-12       Impact factor: 12.969

3.  Short-term prophylaxis with tobramycin and lincomycin in bowel surgery.

Authors:  M R Keighley; A R Crapp
Journal:  Scott Med J       Date:  1976-04       Impact factor: 0.729

Review 4.  Wound infection and topical antibiotics: the surgeon's dilemma.

Authors:  N A Halasz
Journal:  Arch Surg       Date:  1977-10

5.  Surgical sepsis.

Authors:  W E Birkenstock
Journal:  S Afr Med J       Date:  1973-03-10

6.  Intraoperative antibiotic wound lavage: an attempt to eliminate postoperative infection in arterial and clean general surgical procedures.

Authors:  J W Lord; G Rossi; M Daliana
Journal:  Ann Surg       Date:  1977-06       Impact factor: 12.969

7.  Effects of prophylactic antibiotics in vascular surgery. A prospective, randomized, double-blind study.

Authors:  P O Hasselgren; L Ivarsson; B Risberg; T Seeman
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

8.  Serum and tissue concentrations of intravenous cefotaxime during aortic surgery.

Authors:  J V Robbs; A Kharsany
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  Antibiotic prophylaxis in vascular surgery.

Authors:  A B Kaiser; K R Clayson; J L Mulherin; A C Roach; T R Allen; W H Edwards; W A Dale
Journal:  Ann Surg       Date:  1978-09       Impact factor: 12.969

10.  Vascular prosthetic infections: collected experience and results of treatment.

Authors:  W G Liekweg; L J Greenfield
Journal:  Surgery       Date:  1977-03       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.